<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113133</article-id><article-id pub-id-type="publisher-id">ACM-40858</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_34368022.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  酪酸梭菌活菌片对乙肝免疫球蛋白水平影响
  The Effect of Clostridium butyricum Viable Tablet on the Level of Hepatitis B Immunoglobulin
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>红云</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陆</surname><given-names>景锋</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>来海</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>艳艳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>田</surname><given-names>怡</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>曹庚</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>倪</surname><given-names>菊平</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>瑞芳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>上海市闵行区中心医院，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>925</fpage><lpage>929</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨酪酸梭菌活菌片对慢性乙型病毒性肝炎患者肝功能及免疫球蛋白(IgG、IgA、IgM)的影响。方法：收集2018年1月至2019年12月于我院肝炎门诊就诊的慢性乙型肝炎患者40名，采用全自动生化分析仪检测患者治疗前后的肝功能及IgG、IgA、IgM的变化，探讨酪酸梭菌活菌片与慢性乙型病毒性肝炎患者肝功能及IgG、IgA、IgM水平的相关性。结果：酪酸梭菌活菌片对慢性乙型病毒性肝炎患者肝功能及IgG、IgA、IgM水平有显著影响，观察组患者免疫球蛋白指标高于对照组健康成年人，两组间差异存在统计学意义(P &lt; 0.05)；观察组患者治疗前后的免疫球蛋白指标前下降，差异有统计学意义(P &lt; 0.05)。结论：口服酪酸梭菌活菌片可作为治疗慢性HBV感染的新策略。
    Objective: To investigate the effect of Clostridium butyricum viable tablet on liver function, IgG, IgA and IgM in patients with chronic hepatitis B. Methods: We collected 40 patients with chronic hepatitis B who visited the hepatitis clinic in our hospital from January 2018 to December 2019. The liver function and the changes of IgG, IgA and IgM before and after treatment were detected by automatic biochemical analyzer. To explore the correlation between Clostridium butyricum viable tablet and liver function and IgG, IgA and IgM levels in patients with chronic hepatitis B. Results: The Clostridium butyricum viable tablet has significant effect on liver function and the levels of IgG, IgA and IgM in patients with chronic hepatitis B. The immunoglobulin index in the observation group was higher than that in the control group. The difference between the two groups was statistically significant (P &lt; 0.05); the immunoglobulin index of the observation group decreased before and after treatment. The difference between the two groups was statistically significant (P &lt; 0.05). Conclusions: Oral Clostridium butyricum viable tablet can be used as a new strategy for the treatment of chronic HBV infection. 
  
 
</p></abstract><kwd-group><kwd>酪酸梭菌活菌片，乙型肝炎，慢性，免疫球蛋白, Clostridium butyricum Viable Tablet</kwd><kwd> Hepatitis B</kwd><kwd> Chronic</kwd><kwd> Immunoglobulin</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨酪酸梭菌活菌片对慢性乙型病毒性肝炎患者肝功能及免疫球蛋白(IgG、IgA、IgM)的影响。方法：收集2018年1月至2019年12月于我院肝炎门诊就诊的慢性乙型肝炎患者40名，采用全自动生化分析仪检测患者治疗前后的肝功能及IgG、IgA、IgM的变化，探讨酪酸梭菌活菌片与慢性乙型病毒性肝炎患者肝功能及IgG、IgA、IgM水平的相关性。结果：酪酸梭菌活菌片对慢性乙型病毒性肝炎患者肝功能及IgG、IgA、IgM水平有显著影响，观察组患者免疫球蛋白指标高于对照组健康成年人，两组间差异存在统计学意义(P &lt; 0.05)；观察组患者治疗前后的免疫球蛋白指标前下降，差异有统计学意义(P &lt; 0.05)。结论：口服酪酸梭菌活菌片可作为治疗慢性HBV感染的新策略。</p></sec><sec id="s2"><title>关键词</title><p>酪酸梭菌活菌片，乙型肝炎，慢性，免疫球蛋白</p></sec><sec id="s3"><title>The Effect of Clostridium butyricum Viable Tablet on the Level of Hepatitis B Immunoglobulin<sup> </sup></title><p>Hongyun Zhang, Jingfeng Lu, Laihai Zhang, Yanyan Li, Yi Tian, Caogeng Zhang, Juping Ni, Ruifang Xu</p><p>Central Hospital of Minhang District, Shanghai</p><p><img src="//html.hanspub.org/file/16-1571982x4_hanspub.png" /></p><p>Received: Feb. 8<sup>th</sup>, 2021; accepted: Feb. 28<sup>th</sup>, 2021; published: Mar. 10<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/16-1571982x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the effect of Clostridium butyricum viable tablet on liver function, IgG, IgA and IgM in patients with chronic hepatitis B. Methods: We collected 40 patients with chronic hepatitis B who visited the hepatitis clinic in our hospital from January 2018 to December 2019. The liver function and the changes of IgG, IgA and IgM before and after treatment were detected by automatic biochemical analyzer. To explore the correlation between Clostridium butyricum viable tablet and liver function and IgG, IgA and IgM levels in patients with chronic hepatitis B. Results: The Clostridium butyricum viable tablet has significant effect on liver function and the levels of IgG, IgA and IgM in patients with chronic hepatitis B. The immunoglobulin index in the observation group was higher than that in the control group. The difference between the two groups was statistically significant (P &lt; 0.05); the immunoglobulin index of the observation group decreased before and after treatment. The difference between the two groups was statistically significant (P &lt; 0.05). Conclusions: Oral Clostridium butyricum viable tablet can be used as a new strategy for the treatment of chronic HBV infection.</p><p>Keywords:Clostridium butyricum Viable Tablet, Hepatitis B, Chronic, Immunoglobulin</p><disp-formula id="hanspub.40858-formula9"><graphic xlink:href="//html.hanspub.org/file/16-1571982x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/16-1571982x7_hanspub.png" /> <img src="//html.hanspub.org/file/16-1571982x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>酪酸梭菌活菌片胶囊 [<xref ref-type="bibr" rid="hanspub.40858-ref1">1</xref>] 是肠道3种固有菌(粪链球菌、嗜酸乳杆菌及双歧杆菌)的复方制剂，能调整肠道菌群、恢复肠道菌群的生态平衡、激活肠黏膜关联淋巴组织活性，从而提高肠黏膜免疫能力。HBV感染不直接导致肝功能损伤，但其可通过机体免疫反应间接引起肝细胞损伤 [<xref ref-type="bibr" rid="hanspub.40858-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40858-ref3">3</xref>]。本研究比较了经酪酸梭菌活菌片治疗后慢性乙型肝炎肝功能及IgG、IgA、IgM的变化，以探讨酪酸梭菌活菌片对患者体液免疫功能的影响。现总结如下：</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>选取2018年1月至2019年12月于我院肝炎门诊就诊的慢性乙型肝炎患者为研究对象，诊断均符合《慢性乙型肝炎防治指南(2019年版)》的标准 [<xref ref-type="bibr" rid="hanspub.40858-ref4">4</xref>]，排除自酒精性肝炎、药物性肝损伤、身免疫性肝炎、合并感染和其他各种肝病患者。采用区组随机分组法分为研究组 和对照组，各40例。研究组：男性18例，女性22例；年龄35~68岁，平均(48.2 &#177; 6.3)岁；对照组：男性23例，女性17例；年龄38~73岁，平均(51.2 &#177; 7.6)岁。两组患者的性别、年龄、病情等一般资料比较均无明显差异(P &gt; 0.05)，所有入组患者在治疗前均签署治疗知情同意书，对照组予口服保肝药：当飞利肝宁胶囊4粒/次，口服，3次/天。观察组在保肝治疗同时给予以酪酸梭菌活菌片胶囊2粒/次，口服，3次/天，连续治疗8周。本研究获得上海市闵行区中心医院伦理委员会的伦理许可。</p></sec><sec id="s6_2"><title>2.2. 应用全自动生化分析仪检测患者的肝功能水平</title><p>包括ALT、AST、GGT、TBil；采集患者治疗前(基线)、治疗1个月和治疗2个月的血清(若采血时合并明显感染或过敏，则将该患者排除)，−70℃冰箱冷冻保存，采用免疫透射比浊法(试剂购自美国贝克曼公司)统一检测IgG、IgA、IgM。</p></sec><sec id="s6_3"><title>2.3. 统计学处理</title><p>采用SPSS 20.0软件进行数据统计分析。正态分布的计量资料以 x &#175; &#177; s表示，采用t检验，计数资料以百分比表示，采用χ<sup>2</sup>检验。以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 肝功能</title><p>治疗前两组ALT、AST、TBIL、GGT水平比较，差异无统计学意义(P &gt; 0.05)。治疗后两组ALT、AST、TBIL、GGT水平均较治疗前下降(P &lt; 0.05)，且治疗后观察组ALT、AST、TBIL、GGT水平比对照组更低(均P &lt; 0.05)，如表1所示：</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of liver function between two groups ( x &#175; &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >n</th><th align="center" valign="middle"  colspan="2"  >ALT (U/L)</th><th align="center" valign="middle"  colspan="2"  >AST (U/L)</th><th align="center" valign="middle"  colspan="2"  >TBIL (U/L)</th><th align="center" valign="middle"  colspan="2"  >GGT (U/L)</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >147.35 &#177; 15.26</td><td align="center" valign="middle" >82.31 &#177; 8.59</td><td align="center" valign="middle" >133.56 &#177; 14.67</td><td align="center" valign="middle" >75.29 &#177; 9.12</td><td align="center" valign="middle" >27.68 &#177; 9.17</td><td align="center" valign="middle" >17.35 &#177; 6.18</td><td align="center" valign="middle" >87.12 &#177; 13.97</td><td align="center" valign="middle" >48.34 &#177; 9.31</td></tr><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >148.12 &#177; 17.46</td><td align="center" valign="middle" >53.27 &#177; 7.54</td><td align="center" valign="middle" >136.38 &#177; 16.51</td><td align="center" valign="middle" >48.95 &#177; 8.05</td><td align="center" valign="middle" >28.15 &#177; 8.34</td><td align="center" valign="middle" >14.29 &#177; 5.67</td><td align="center" valign="middle" >88.23 &#177; 15.16</td><td align="center" valign="middle" >39.57 &#177; 8.62</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2.132</td><td align="center" valign="middle" >3.649</td><td align="center" valign="middle" >0.203</td><td align="center" valign="middle" >2.664</td><td align="center" valign="middle" >1.615</td><td align="center" valign="middle" >3.874</td><td align="center" valign="middle" >1.025</td><td align="center" valign="middle" >3.270</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.964</td><td align="center" valign="middle" >0.026</td><td align="center" valign="middle" >0.872</td><td align="center" valign="middle" >0.017</td><td align="center" valign="middle" >0.956</td><td align="center" valign="middle" >0.034</td><td align="center" valign="middle" >0.871</td><td align="center" valign="middle" >0.035</td></tr></tbody></table></table-wrap><p>表1. 两组患者肝功能比较( x &#175; &#177; s)</p><p>注：与对照组治疗后比较，P &lt; 0.05。</p></sec><sec id="s7_2"><title>3.2. 两组间免疫球蛋白差异</title><p>治疗前两组IgG、IgA、IgM水平比较，差异无统计学意义(P &gt; 0.05)。治疗后两组IgG、IgA、IgM水平均较治疗前下降(P &lt; 0.05)，且治疗后观察组IL-6、IL-8、TNF-α水平比对照组更低(P &lt; 0.05)。如表2所示：</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of inflammatory factors between two groups ( x &#175; &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >n</th><th align="center" valign="middle"  colspan="2"  >IgG (g/L)</th><th align="center" valign="middle"  colspan="2"  >IgA (g/L)</th><th align="center" valign="middle"  colspan="2"  >IgM (g/ml)</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >17.62 &#177; 0.51</td><td align="center" valign="middle" >12.45 &#177; 2.76</td><td align="center" valign="middle" >4.71 &#177; 0.43</td><td align="center" valign="middle" >36.2 &#177; 4.5</td><td align="center" valign="middle" >3.28 &#177; 0.3</td><td align="center" valign="middle" >0.60 &#177; 0.14</td></tr><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >38.91 &#177; 8.84</td><td align="center" valign="middle" >7.85 &#177; 2.22</td><td align="center" valign="middle" >56.2 &#177; 7.1</td><td align="center" valign="middle" >21.4 &#177; 1.5</td><td align="center" valign="middle" >2.57 &#177; 0.43</td><td align="center" valign="middle" >1.28 &#177; 0.25</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.024</td><td align="center" valign="middle" >4.215</td><td align="center" valign="middle" >0.257</td><td align="center" valign="middle" >3.216</td><td align="center" valign="middle" >0.984</td><td align="center" valign="middle" >3.012</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.964</td><td align="center" valign="middle" >0.013</td><td align="center" valign="middle" >0.867</td><td align="center" valign="middle" >0.017</td><td align="center" valign="middle" >0.904</td><td align="center" valign="middle" >0.015</td></tr></tbody></table></table-wrap><p>表2. 两组患者炎症因子比较( x &#175; &#177; s)</p><p>注：与对照组治疗后比较，P &lt; 0.05。</p><p>观察组患者免疫球蛋白指标高于对照组健康成年人，如表3所示：</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Differences in immunoglobulin between the two groups (g/L</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数(n)</th><th align="center" valign="middle" >IgG</th><th align="center" valign="middle" >IgA</th><th align="center" valign="middle" >IgM</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >17.62 &#177; 0.51</td><td align="center" valign="middle" >4.71 &#177; 0.43</td><td align="center" valign="middle" >3.28 &#177; 0.3</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >5.92 &#177; 0.65</td><td align="center" valign="middle" >1.55 &#177; 0.26</td><td align="center" valign="middle" >1.3 &#177; 0.1</td></tr></tbody></table></table-wrap><p>表3. 两组间免疫球蛋白差异(单位：g/L)</p></sec><sec id="s7_3"><title>3.3. 观察组患者治疗前后的免疫球蛋白指标差异</title><p>观察组患者治疗后的免疫球蛋白指标好转，如表4所示：</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Difference of immunoglobulins between patients in observation group before and after treatment (g/L</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >IgG</th><th align="center" valign="middle" >IgA</th><th align="center" valign="middle" >IgM</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >14.58 &#177; 4.12</td><td align="center" valign="middle" >3.56 &#177; 0.23</td><td align="center" valign="middle" >1.41 &#177; 0.08</td></tr><tr><td align="center" valign="middle" >治疗1个月</td><td align="center" valign="middle" >12.91 &#177; 2.71</td><td align="center" valign="middle" >2.19 &#177; 0.68</td><td align="center" valign="middle" >1.08 &#177; 0.05</td></tr><tr><td align="center" valign="middle" >治疗2个月</td><td align="center" valign="middle" >6.93 &#177; 2.34</td><td align="center" valign="middle" >1.62 &#177; 0.31</td><td align="center" valign="middle" >1.52 &#177; 0.08</td></tr></tbody></table></table-wrap><p>表4. 观察组患者治疗前后的免疫球蛋白指标差异(单位：g/L)</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>免疫球蛋白 [<xref ref-type="bibr" rid="hanspub.40858-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.40858-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.40858-ref7">7</xref>] 是一种具有抗体活性的血浆球蛋白，其水平越高提示患者体液免疫亢进，机体内免疫球蛋白依据重链恒定区的结构不同而分为5种(IgG、IgM、IgA、IgE、IgD)，其水平升高与多种疾病有关。本研究选取其中3种进行检测，其中IgG为免疫球蛋白的主要成分，与血清抗体活动有关，是唯一可通过胎盘的抗体，也是机体抗感染的主力抗体；IgA为外分泌型免疫球蛋白，而慢性肝炎组血清球蛋白较健康对照组明显增加。免疫球蛋白抗体存在于患者血清中，也存在于其他体液中，可与抗原结合，识别抗原分子，阻止病毒对靶细胞的感染 [<xref ref-type="bibr" rid="hanspub.40858-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.40858-ref9">9</xref>]，该功能又需要借助免疫球蛋白 G、免疫球蛋白A、免疫球蛋白M等多种免疫球蛋白具体起效。</p><p>慢性乙型肝炎患者体内乙肝病毒持续感染，致使病情迁延不愈，部分患者肝细胞被反复破坏，纤维化形成，最后演变成肝硬化甚至肝癌 [<xref ref-type="bibr" rid="hanspub.40858-ref10">10</xref>]。有研究认为，乙肝病毒的繁殖和复制不是造成肝损伤的主要原因，而根源是乙肝病毒侵入人体后，刺激机体对自身肝细胞产生免疫反应，从而引起肝细胞病理性免疫损伤 [<xref ref-type="bibr" rid="hanspub.40858-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.40858-ref12">12</xref>]。乙肝病毒抗原在肝细胞内持续存在，刺激B淋巴细胞增殖分化，分泌免疫球蛋白。慢性乙型肝炎患者体液免疫功能亢进，表现为肝功能及IgG、IgA、IgM水平异常升高，这对肝炎疾病的诊断具有临床价值。</p><p>益生菌 [<xref ref-type="bibr" rid="hanspub.40858-ref13">13</xref>] 可改善乙肝患者肠道屏障功能，降低体内炎性因子水平。本研究中经酪酸梭菌活菌片治疗后所有患者肝功能及IgG、IgA、IgMIgG、IgM和IgA水平均有所下降，其原因可能是酪酸梭菌活菌片中的益生菌活性佳，可在肠道内快速繁殖，进而提高结直肠中有益细菌比例，优化机体营养吸收，抑制致病菌引发的炎性反应，改善肠道黏膜细胞免疫功能，刺激机体合成免疫球蛋白的能力也随之下降；本研究表明经酪酸梭菌活菌片治疗后慢性乙型肝炎患者血清免疫球蛋白IgG、IgM、IgA水平均有不同程度下降，表明酪酸梭菌活菌片调节肠道菌群改善肠道免疫力有助于患者体液免疫功能的恢复，可作为治疗慢性HBV感染的新策略。</p></sec><sec id="s9"><title>基金项目</title><p>上海市闵行区卫生健康委员会科研课题专项项目(编号：2020MW22)。</p></sec><sec id="s10"><title>文章引用</title><p>张红云,陆景锋,张来海,李艳艳,田 怡,张曹庚,倪菊平,徐瑞芳. 酪酸梭菌活菌片对乙肝免疫球蛋白水平影响The Effect of Clostridium butyricum Viable Tablet on the Level of Hepatitis B Immunoglobulin[J]. 临床医学进展, 2021, 11(03): 925-929. https://doi.org/10.12677/ACM.2021.113133</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40858-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">江泳, 关玉龙, 韩小玲, 等. 酪酸梭菌活菌片散联合水飞蓟宾胶囊治疗非酒精性脂肪性肝病患者的临床研究[J]. 中国临床药理学杂志, 2020, 36(15): 2212-2215.</mixed-citation></ref><ref id="hanspub.40858-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">徐莹莹, 龚建玲, 严亚丹, 等. 慢性乙型肝炎病毒感染者血清脂联素水平与体液免疫功能的相关性研究[J]. 现代实用医学, 2016, 28(5): 592-594.</mixed-citation></ref><ref id="hanspub.40858-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">张云云, 张琳, 刘洁, 等. 免疫球蛋白检验在慢性乙型肝炎患者中的应用价值[J]. 临床医学研究与实践, 2020, 5(19): 95-96+99.</mixed-citation></ref><ref id="hanspub.40858-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">王贵强, 王福生, 庄辉, 等. 慢性乙型肝炎防治指南(2019年版) [J]. 中华实验和临床感染病杂志(电子版), 2019, 13(06): 441-466.</mixed-citation></ref><ref id="hanspub.40858-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">张利娥, 李娜, 等. 双歧杆菌乳杆菌三联活菌片对肝硬化自发性腹膜炎患者血清CRP、IL-2的影响[J]. 现代消化及介入诊疗, 2018, 23(4): 483-485.</mixed-citation></ref><ref id="hanspub.40858-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">梁丹红, 黄换桂, 郭凤媚, 等. 不同自身免疫性肝病患者肝功能及IgG、IgA、IgMG4水平差异分析[J]. 中国医学工程, 2016, 24(7): 79-80.</mixed-citation></ref><ref id="hanspub.40858-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">徐莹莹, 龚建玲, 严亚丹, 等. 慢性乙型肝炎病毒感染者血清脂联素水平与体液免疫功能的相关性研究[J]. 现代实用医学, 2016, 28(5): 592-594.</mixed-citation></ref><ref id="hanspub.40858-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">杨晓婷, 赖广华, 卓李圆, 等. 血清甲状腺激素、免疫球蛋白的表达与慢性乙型肝炎的相关性研究[J]. 中国病案, 2018, 19(9): 99-101.</mixed-citation></ref><ref id="hanspub.40858-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">许庆, 徐元宏. 慢性肝病患者血小板与血清IgG水平变化及意义[J]. 山东医药, 2016, 56(37): 96-98.</mixed-citation></ref><ref id="hanspub.40858-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">陈益泉, 等. 浅谈对慢性乙肝所致肝衰竭患者进行血清IgG、IgM及IgA检测的意义[J]. 当代医药论丛, 2016, 14(19): 87-88.</mixed-citation></ref><ref id="hanspub.40858-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">徐莹莹, 龚建玲, 严亚丹, 等. 慢性乙型肝炎病毒感染者血清脂联素水平与体液免疫功能的相关性研究[J]. 现代实用医学, 2016, 28(5): 592-594.</mixed-citation></ref><ref id="hanspub.40858-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">李雷花等. 肝功能及IgG、IgA、IgMIgG和IgM及IgA水平的检测对慢性乙肝肝衰竭的诊断价值[J]. 内蒙古医学杂志, 2019, 51(10): 1226-1227.</mixed-citation></ref><ref id="hanspub.40858-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">中华预防医学会微生态学分会. 中国微生态调节剂临床应用专家共识(2020版) [J]. 中国微生态学杂志, 2020, 32(8): 953-965.</mixed-citation></ref></ref-list></back></article>